Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | NRAS |
Variant | wild-type |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | Wild-type NRAS indicates that no mutation has been detected within the NRAS gene. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT02785068 | Phase I | Fluorouracil + Irinotecan + Leucovorin + MM-151 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Withdrawn | 0 | |
NCT04616183 | Phase Ib/II | Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02568046 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + SYM004 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | Terminated | USA | ESP | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Unknown status | USA | 0 |
NCT01312857 | Phase II | Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | Completed | USA | 0 |
NCT03457896 | Phase II | Cetuximab + Neratinib Neratinib + Trastuzumab | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | Unknown status | USA | 0 |
NCT03069950 | Phase II | Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | Withdrawn | USA | 0 |
NCT01937715 | Phase II | Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | Terminated | USA | ESP | CAN | 0 |
NCT01960023 | Phase Ib/II | Cetuximab + Neratinib | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT02508077 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03668431 | Phase II | Dabrafenib + Spartalizumab + Trametinib | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Unknown status | USA | 0 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT04169347 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02713373 | Phase Ib/II | Cetuximab + Pembrolizumab | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02573220 | Phase I | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | Withdrawn | ITA | 0 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | GBR | ESP | 1 |
NCT03384940 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Completed | USA | ITA | GBR | ESP | 1 |
NCT02205398 | Phase Ib/II | Capmatinib + Cetuximab | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 0 |
NCT03300609 | Phase III | Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Terminated | USA | 0 |
NCT03580382 | Phase Ib/II | CDX-3379 + Trametinib | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | Terminated | USA | 0 |